CAR-T To N-of-1 Studies: How Jeeva Is Helping Drive Trial Efficiencies
July 17, 2024
Source: SCRIP CITELINE COMMERCIAL Jeeva’s founder and CEO talks to Scrip about how the firm’s clinical trial management platform does away with the need for
Source: SCRIP CITELINE COMMERCIAL Jeeva’s founder and CEO talks to Scrip about how the firm’s clinical trial management platform does away with the need for
Source: PRWeb Remarkable progress in the development of cell and gene therapies (CGTx) has ignited hope for millions of patients battling debilitating human diseases including Central
Source: PM360online Enhancing patient engagement in rare disease support programs requires tailored strategies that leverage innovative approaches, including AI and decentralized trials: Personalized Communication: Utilize
Source: IG Living Magazine Research and development of orphan drugs is time-consuming and costly, and appropriate participants for clinical trials are hard to find. Efficiently
Source: PR Web President Biden’s loss of his beloved son to brain cancer in 2015 inspired the Cancer Moonshot initiative. Dr. Harsha Rajasimha’s inspiration for
Source: PRWeb Jeeva Clinical Trials is revolutionizing drug development by integrating AI and automated workflows into clinical trials, significantly reducing the time and cost of
Source: Western Pennsylvania Healthcare News The recent Food and Drug Administration (FDA) approval of cell-based gene therapies for Sickle Cell Disease (SCD) marks a groundbreaking
Source: Rare Disease and Orphan Drug Journal Abstract One of the main challenges in rare diseases is the unavailability of reliable estimates of prevalence and
Source: Dermatology Times Gender gaps, with consistent underrepresentation of females, present a substantial challenge in clinical research.(1) Achieving a balanced representation of both genders has
Source: The Company of Biologists Rare diseases affect only a few people in a given population but, collectively, they impact over 400 million people globally
Source: Polite On Society Greetings, everyone. Diversity in medicine in today’s society is important. This week, we hear from Dr. Harsha Rajasimha, Ph.D., Founder and
Source: PRWeb The Food and Drug Administration has approved 16 new gene therapies to date, but for most people around the world, these expensive treatments
Source: PRWeb The cost of patients dropping out of clinical trials continues to be a major problem for the development of new drugs and treatments
Source: PRWeb Dr. Harsha Rajasimha, Founder and CEO of Jeeva Trials, highlights the importance and value of Investigator-Initiated Trials (IITs) in gathering real-world data on
Source: Onco’Zine The Inflation Reduction Act of 2022 (IRA) covers new and reinstated tax laws that will affect individuals and businesses. Through IRA, President Joe
Source: PRWeb Drug pricing controls imposed by the Inflation Reduction Act of 2022 may appear positive for patients in the short term. However, these controls
Source: EIN News CCF grants support startups, critical early technology testing and market validation efforts. RICHMOND, VIRGINIA, UNITED STATES, June 27, 2023/EINPresswire.com/ — The Virginia
Source: Cision PRweb The FDA has released new guidance for decentralized clinical trials (DCTs) for drugs, biological products, and medical devices to improve DCT implementation.
Source: PR Distribution Genomics expert and social entrepreneur, Harsha Rajasimha, looks to bridge OMICS and Exposure Health with partner DailyBreath at the inaugural total exposure
Source: Cision PRweb The value of life-saving drugs for patients suffering from serious diseases is priceless. But the current economic environment is stifling the biopharmaceutical
Jeeva Clinical Trials Inc.